Bijender Kumar Bajaj
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Bijender Kumar Bajaj has a total of 162 co-authors. Here are the top co-authors by number of shared publications:
Surbhi Sharma
School of Biotechnology, University of Jammu, Jammu, India
17 shared publicationsParushi Nargotra
Department of Seafood Science, National Kaohsiung University of Science and Technology, Kaohsiung, 811, Taiwan
16 shared publications- Vishal Sharma
Institute of Forensic Science and Criminology, Panjab University, Chandigarh, India
15 shared publications Ridhika Bangotra
School of Biotechnology, University of Jammu, Jammu, 180006, India
13 shared publicationsSurbhi Vaid
School of Biotechnology, University of Jammu, Jammu, India
13 shared publicationsNisha Kapoor
School of Biotechnology, University of Jammu, Jammu, India
11 shared publications
Latest Publications
- 19 August 2026
- Published by Springer Nature in Biomass Conversion and Biorefinery
- Vol. 16 (16) , 315
Ionic liquids as a potential pretreatment strategy for lignocellulosic feedstocks for sustainable bioproducts
- 19 August 2026
- Published by Springer Nature in Biomass Conversion and Biorefinery
- Vol. 16 (16) , 315
Ionic liquids as a potential pretreatment strategy for lignocellulosic feedstocks for sustainable bioproducts
- 25 March 2026
- Published by Springer Nature in Waste and Biomass Valorization
- Vol. 17 (10) , 6327-6351
An Integrated Bioprocess Development for Biofuel Ethanol Production from Wild Grass Saccharum spontaneum Biomass
- 25 March 2026
- Published by Springer Nature in Waste and Biomass Valorization
- Vol. 17 (10) , 6327-6351
An Integrated Bioprocess Development for Biofuel Ethanol Production from Wild Grass Saccharum spontaneum Biomass
- 26 December 2025
- Published by Springer Nature in Probiotics and Antimicrobial Proteins
- Vol. 18 (4) , 5289-5311
Therapeutic Potential and Functional Mechanisms of Probiotics as Prospective anti-inflammatory Agents
Inflammation triggered by injury, infection, or exposure to chemicals results in chronic diseases, and constitutes the leading cause of death worldwide. Anti-inflammatory drugs available for the treatment of inflammation mainly leads to side effects like ulcers or kidney damage which necessitate the need for safer alternatives of these drugs. Probiotics, live beneficial microorganisms, have garnered significant attention for their role in modulating immune responses and reducing the inflammation, and are generally considered as safe. Probiotics aid in reducing inflammation by improving gut health and immune balance. The anti-inflammatory potential of probiotics aids in preventing and managing chronic inflammatory conditions, including inflammatory bowel disease (IBD), arthritis, autoimmune diseases and metabolic disorders. Mechanistically, probiotics modulate immune responses by increasing the production of anti-inflammatory cytokines such as interleukin-10 (IL-10) and the activity of regulatory T cells (Tregs), while down regulating pro-inflammatory cytokines like tumor necrosis factor-alpha (TNF-α) and interleukin-6 (IL-6). Some strains, such as Lactobacillus and Bifidobacterium, have demonstrated significant anti-inflammatory potential. Probiotic bacteria also exhibit antioxidant potential thereby, reducing the oxidative stress which is a key driver of chronic inflammation. This review explores the anti-inflammatory properties of probiotics, highlighting their mechanisms of action, including modulation of gut microbiota, enhancement of intestinal barrier integrity, regulation of immune responses, and production of bioactive metabolites. Furthermore, the current review discusses the therapeutic applications of probiotics in managing inflammatory diseases and the challenges associated with their usage. Therefore, understanding anti-inflammatory potential of probiotics could open new avenues for non-pharmacological interventions in inflammatory and autoimmune disorders.
- 26 December 2025
- Published by Springer Nature in Probiotics and Antimicrobial Proteins
- Vol. 18 (4) , 5289-5311
Therapeutic Potential and Functional Mechanisms of Probiotics as Prospective anti-inflammatory Agents
Inflammation triggered by injury, infection, or exposure to chemicals results in chronic diseases, and constitutes the leading cause of death worldwide. Anti-inflammatory drugs available for the treatment of inflammation mainly leads to side effects like ulcers or kidney damage which necessitate the need for safer alternatives of these drugs. Probiotics, live beneficial microorganisms, have garnered significant attention for their role in modulating immune responses and reducing the inflammation, and are generally considered as safe. Probiotics aid in reducing inflammation by improving gut health and immune balance. The anti-inflammatory potential of probiotics aids in preventing and managing chronic inflammatory conditions, including inflammatory bowel disease (IBD), arthritis, autoimmune diseases and metabolic disorders. Mechanistically, probiotics modulate immune responses by increasing the production of anti-inflammatory cytokines such as interleukin-10 (IL-10) and the activity of regulatory T cells (Tregs), while down regulating pro-inflammatory cytokines like tumor necrosis factor-alpha (TNF-α) and interleukin-6 (IL-6). Some strains, such as Lactobacillus and Bifidobacterium, have demonstrated significant anti-inflammatory potential. Probiotic bacteria also exhibit antioxidant potential thereby, reducing the oxidative stress which is a key driver of chronic inflammation. This review explores the anti-inflammatory properties of probiotics, highlighting their mechanisms of action, including modulation of gut microbiota, enhancement of intestinal barrier integrity, regulation of immune responses, and production of bioactive metabolites. Furthermore, the current review discusses the therapeutic applications of probiotics in managing inflammatory diseases and the challenges associated with their usage. Therefore, understanding anti-inflammatory potential of probiotics could open new avenues for non-pharmacological interventions in inflammatory and autoimmune disorders.
- 5 December 2025
- Published by Elsevier
Contributors
- 21 November 2025
- Published by Springer Nature in Environmental Sustainability
- Vol. 8 (4) , 815-829
Catalytic potential of metallic oxide nanoparticles for enhancing the ionic liquid mediated bioconversion of sugarcane tops biomass to biofuel-ethanol
- 21 November 2025
- Published by Springer Nature in Environmental Sustainability
- Vol. 8 (4) , 815-829
Catalytic potential of metallic oxide nanoparticles for enhancing the ionic liquid mediated bioconversion of sugarcane tops biomass to biofuel-ethanol
- 13 June 2025
- Published by Springer Nature in Environmental Sustainability
- Vol. 8 (2) , 355-366
Microwave-assisted deep eutectic solvent pretreatment of Saccharum spontaneum biomass for biofuel-ethanol production using one pot consolidated processing
- 13 June 2025
- Published by Springer Nature in Environmental Sustainability
- Vol. 8 (2) , 355-366
Microwave-assisted deep eutectic solvent pretreatment of Saccharum spontaneum biomass for biofuel-ethanol production using one pot consolidated processing
- Open Access
- 1 January 2025
- Published by CSIR-National Institute of Science Communication and Policy Research (NIScPR) in Indian Journal of Experimental Biology
- Vol. 63 (03) , 252-263
Bioprospecting of probiotic lactic acid bacteria from jalebi batter and evaluation of their antidiabetic and antioxidant potential
Diabetes has become the most commonly prevalent metabolic disorder worldwide. Though the medications are available for effective management of hyperglycemia due to diabetes but most of them have adverse side effects. Therefore, there is immense emphasis on the exploration of safer alternatives for managing diabetes. One such safe alternative may be the application of probiotics for the effectual control/management of diabetes. In the current study, sixteen lactic acid bacteria (LAB) were isolated from jalebi batter, a rarely explored ecological niche, for potential probiotics. These isolates were evaluated for their fundamental probiotic characteristics, with seven isolates demonstrating robust survival rates ranging from 87.6% to 96.8% in simulated gastrointestinal conditions. Additionally, these selected LAB isolates displayed noteworthy functional attributes viz. hydrophobicity, autoaggregation, and coaggregation capabilities. Furthermore, the LAB isolates were investigated for antibiotic susceptibility, antibacterial activity and antioxidant potential. Moreover, LAB isolates from the jalebi batter were examined for their inhibition potential against α-glucosidase and α-amylase enzymes via both intact cells (IC) and cell-free supernatants (CFS). Notably, LAB isolate J-7 exhibited the highest inhibition of α-glucosidase (CFS: 72.27%; IC: 11.90%) and α-amylase (CFS: 15.21%; IC: 13.04%), and also possessed other functionally desired probiotic attributes. The LAB isolate J-7 was identified based on 16S rDNA sequencing as Limosilactobacillus fermentum, and designated as L. fermentum PP556213 strain J-7.
- 1 January 2025
- Published by CSIR-National Institute of Science Communication and Policy Research (NIScPR) in Indian Journal of Experimental Biology
- Vol. 63 (03) , 252-263
Open AccessBioprospecting of probiotic lactic acid bacteria from jalebi batter and evaluation of their antidiabetic and antioxidant potential
Diabetes has become the most commonly prevalent metabolic disorder worldwide. Though the medications are available for effective management of hyperglycemia due to diabetes but most of them have adverse side effects. Therefore, there is immense emphasis on the exploration of safer alternatives for managing diabetes. One such safe alternative may be the application of probiotics for the effectual control/management of diabetes. In the current study, sixteen lactic acid bacteria (LAB) were isolated from jalebi batter, a rarely explored ecological niche, for potential probiotics. These isolates were evaluated for their fundamental probiotic characteristics, with seven isolates demonstrating robust survival rates ranging from 87.6% to 96.8% in simulated gastrointestinal conditions. Additionally, these selected LAB isolates displayed noteworthy functional attributes viz. hydrophobicity, autoaggregation, and coaggregation capabilities. Furthermore, the LAB isolates were investigated for antibiotic susceptibility, antibacterial activity and antioxidant potential. Moreover, LAB isolates from the jalebi batter were examined for their inhibition potential against α-glucosidase and α-amylase enzymes via both intact cells (IC) and cell-free supernatants (CFS). Notably, LAB isolate J-7 exhibited the highest inhibition of α-glucosidase (CFS: 72.27%; IC: 11.90%) and α-amylase (CFS: 15.21%; IC: 13.04%), and also possessed other functionally desired probiotic attributes. The LAB isolate J-7 was identified based on 16S rDNA sequencing as Limosilactobacillus fermentum, and designated as L. fermentum PP556213 strain J-7.